US › Healthcare

Alto Neuroscience, Inc. (ANRO)

US · Healthcare · Biotechnology

$28.23+3.52%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-26.2M
Profit YoY
-73.0%
EPS
$-0.80
EPS estimate
$-0.50

EPS came in at -0.80 against a street estimate of -0.50 — a miss of 60.0%.

Key statistics

Market cap
$957.0M
Forward P/E
0.0
P/B
4.32
Book value
$6.94
EPS (TTM)
$-2.43
52-week high
$28.85
52-week low
$3.00
50-day MA
$24.01
200-day MA
$19.55
Beta
1.09

Analyst view

Analysts rate Alto Neuroscience, Inc. a strong buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $35.13.

Shareholding

Insiders
4.11%
Institutions
80.41%

Largest institutional holders

FundStake
Alpha Wave Global LP10.57%
COMMODORE CAPITAL LP7.76%
Vestal Point Capital LP5.88%
Perceptive Advisors LLC5.73%
Vanguard Group Inc3.89%
Spruce Street Capital LP3.78%
Vanguard Capital Management, LLC3.44%
Franklin Resources Inc3.14%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Alto Neuroscience, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.